KR100768488B1 - 글리코펩티드 포스포네이트 유도체 - Google Patents

글리코펩티드 포스포네이트 유도체 Download PDF

Info

Publication number
KR100768488B1
KR100768488B1 KR1020027017472A KR20027017472A KR100768488B1 KR 100768488 B1 KR100768488 B1 KR 100768488B1 KR 1020027017472 A KR1020027017472 A KR 1020027017472A KR 20027017472 A KR20027017472 A KR 20027017472A KR 100768488 B1 KR100768488 B1 KR 100768488B1
Authority
KR
South Korea
Prior art keywords
substituted
alkyl
glycopeptide
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027017472A
Other languages
English (en)
Korean (ko)
Other versions
KR20030032970A (ko
Inventor
마이클 알. 리드베터
마틴 에스. 린셀
Original Assignee
세라밴스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 인코포레이티드 filed Critical 세라밴스 인코포레이티드
Publication of KR20030032970A publication Critical patent/KR20030032970A/ko
Application granted granted Critical
Publication of KR100768488B1 publication Critical patent/KR100768488B1/ko
Assigned to 세라밴스 바이오파마 안티바이오틱스 아이피, 엘엘씨 reassignment 세라밴스 바이오파마 안티바이오틱스 아이피, 엘엘씨 권리의 전부이전등록 Assignors: 세라밴스 인코포레이티드
Assigned to 큠버랜드 파마슈티컬즈 인코포레이티드 reassignment 큠버랜드 파마슈티컬즈 인코포레이티드 권리의 전부이전등록 Assignors: 세라밴스 바이오파마 안티바이오틱스 아이피, 엘엘씨
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020027017472A 2000-06-22 2001-05-01 글리코펩티드 포스포네이트 유도체 Expired - Lifetime KR100768488B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
US60/213,410 2000-06-22

Publications (2)

Publication Number Publication Date
KR20030032970A KR20030032970A (ko) 2003-04-26
KR100768488B1 true KR100768488B1 (ko) 2007-10-18

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017472A Expired - Lifetime KR100768488B1 (ko) 2000-06-22 2001-05-01 글리코펩티드 포스포네이트 유도체

Country Status (36)

Country Link
US (10) US6635618B2 (https=)
EP (1) EP1292612B1 (https=)
JP (2) JP3900491B2 (https=)
KR (1) KR100768488B1 (https=)
CN (1) CN100469788C (https=)
AR (1) AR035333A1 (https=)
AT (1) ATE337334T1 (https=)
AU (2) AU2001261107B2 (https=)
BR (1) BRPI0111222B8 (https=)
CA (2) CA2411590C (https=)
CY (2) CY1105194T1 (https=)
CZ (1) CZ303672B6 (https=)
DE (2) DE60122516T2 (https=)
DK (1) DK1292612T3 (https=)
EA (1) EA005953B1 (https=)
EG (1) EG26726A (https=)
ES (1) ES2271012T3 (https=)
HK (1) HK1052191B (https=)
HR (1) HRP20020888B1 (https=)
HU (2) HU229370B1 (https=)
IL (1) IL152408A (https=)
IS (1) IS2303B (https=)
LU (1) LU91908I2 (https=)
MX (1) MXPA02012745A (https=)
MY (1) MY127081A (https=)
NO (2) NO330360B1 (https=)
NZ (1) NZ522279A (https=)
PL (1) PL207101B1 (https=)
PT (1) PT1292612E (https=)
RS (1) RS50499B (https=)
SI (1) SI1292612T1 (https=)
SK (1) SK287470B6 (https=)
TW (1) TWI305209B (https=)
UA (1) UA75083C2 (https=)
WO (1) WO2001098328A2 (https=)
ZA (1) ZA200209419B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69908819T2 (de) * 1998-12-23 2004-05-06 Theravance, Inc., South San Francisco Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
EP1507796B1 (en) 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2003106399A2 (en) 2002-06-17 2003-12-24 Theravance, Inc. PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
ATE381957T1 (de) 2003-07-22 2008-01-15 Theravance Inc Verwendung eines antimykotischen echinocandin- mittels in kombination mit einem antibakteriellen glycopeptid-mittel
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
CN101395164A (zh) * 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
EP2097440A4 (en) 2006-12-22 2010-09-08 Targanta Therapeutics Inc ANTIBIOTICS BASED ON GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES PHOSPHONES AND THEIR USES IN THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
JP5620272B2 (ja) 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
CN101959849A (zh) * 2007-12-26 2011-01-26 利德治疗公司 作为抗菌剂的新型半合成糖肽
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
AU2010245097B2 (en) 2009-04-28 2015-08-13 Melinta Therapeutics, Inc. Methods of treating bacterial infections using oritavancin
SG175401A1 (en) 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US20110009596A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
MY170076A (en) 2010-11-05 2019-07-03 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2013034675A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
EP2753637A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
WO2014132134A1 (en) 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
TN2017000358A1 (en) 2015-02-23 2019-01-16 Theravance Biopharma Antibiotics Ip Llc Doses and methods of administering telavancin
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
KR20190005940A (ko) 2016-05-09 2019-01-16 셀리아 파마슈티칼즈 에이피에스 안정화된 글리코펩티드 항생제 제형
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
US20220024980A1 (en) * 2018-11-21 2022-01-27 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
AU672862B2 (en) 1992-12-02 1996-10-17 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
MY128335A (en) * 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
EP1025852A4 (en) * 1997-10-03 2001-11-07 Fujisawa Pharmaceutical Co VANCOMYCIN ANTIBIOTIC HYDROCHLORIDES AND METHOD FOR THE PRODUCTION THEREOF
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
NZ509165A (en) * 1998-07-14 2003-08-29 Univ Princeton Glycopeptide antobiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
DE69908819T2 (de) * 1998-12-23 2004-05-06 Theravance, Inc., South San Francisco Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
AU4054900A (en) 1999-04-02 2000-10-23 Advanced Medicine East, Inc. Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
BR0112393A (pt) 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
AU2001259302A1 (en) 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
US6620781B2 (en) 2000-06-22 2003-09-16 Theravance, Inc. Glycopeptide carboxy-saccharide derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives

Also Published As

Publication number Publication date
SK18522002A3 (sk) 2003-06-03
TWI305209B (en) 2009-01-11
PT1292612E (pt) 2006-12-29
MY127081A (en) 2006-11-30
CZ20023942A3 (cs) 2003-03-12
HU229370B1 (hu) 2013-11-28
US20040063916A1 (en) 2004-04-01
HRP20020888A2 (en) 2005-02-28
CY2012006I2 (el) 2016-06-22
HK1052191B (en) 2007-01-26
CY1105194T1 (el) 2010-03-03
HUP0301320A3 (en) 2007-05-29
US8101575B2 (en) 2012-01-24
AR035333A1 (es) 2004-05-12
DK1292612T3 (da) 2007-01-02
UA75083C2 (uk) 2006-03-15
IS2303B (is) 2007-10-15
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
NO2011025I1 (no) 2011-11-18
US7208471B2 (en) 2007-04-24
CZ303672B6 (cs) 2013-02-20
JP2007045842A (ja) 2007-02-22
CN1437611A (zh) 2003-08-20
ZA200209419B (en) 2004-02-19
US20060063706A1 (en) 2006-03-23
HUS1400024I1 (hu) 2017-03-28
SK287470B6 (sk) 2010-10-07
YU96902A (sh) 2006-01-16
US20120283195A1 (en) 2012-11-08
NO20025954D0 (no) 2002-12-11
AU2001261107B2 (en) 2006-07-20
WO2001098328A2 (en) 2001-12-27
MXPA02012745A (es) 2004-04-05
SI1292612T1 (sl) 2006-12-31
US6887976B2 (en) 2005-05-03
DE60122516D1 (de) 2006-10-05
NO20025954L (no) 2002-12-11
CY2012006I1 (el) 2016-06-22
EP1292612A2 (en) 2003-03-19
US20100160211A1 (en) 2010-06-24
HK1052191A1 (en) 2003-09-05
NO2011025I2 (https=) 2011-11-18
US20140024604A1 (en) 2014-01-23
NZ522279A (en) 2004-07-30
BRPI0111222B1 (pt) 2015-03-17
PL207101B1 (pl) 2010-11-30
CA2713965A1 (en) 2001-12-27
IL152408A (en) 2009-05-04
EA005953B1 (ru) 2005-08-25
DE60122516T2 (de) 2007-01-04
EP1292612B1 (en) 2006-08-23
IL152408A0 (en) 2003-05-29
KR20030032970A (ko) 2003-04-26
LU91908I2 (fr) 2012-01-30
US20080312407A1 (en) 2008-12-18
CA2411590A1 (en) 2001-12-27
AU6110701A (en) 2002-01-02
HUP0301320A2 (hu) 2003-08-28
CA2411590C (en) 2010-10-19
JP3900491B2 (ja) 2007-04-04
CN100469788C (zh) 2009-03-18
BRPI0111222B8 (pt) 2021-05-25
JP2004501161A (ja) 2004-01-15
ATE337334T1 (de) 2006-09-15
EA200300050A1 (ru) 2003-04-24
US6872701B2 (en) 2005-03-29
DE122011100062I1 (de) 2012-03-15
WO2001098328A3 (en) 2002-04-11
EG26726A (en) 2014-06-18
US7351691B2 (en) 2008-04-01
US20030207797A1 (en) 2003-11-06
ES2271012T3 (es) 2007-04-16
US20050164916A1 (en) 2005-07-28
BR0111222A (pt) 2003-04-01
HRP20020888B1 (en) 2007-12-31
NO330360B1 (no) 2011-04-04
US7008923B2 (en) 2006-03-07
US8859506B2 (en) 2014-10-14
RS50499B (sr) 2010-03-02
PL359419A1 (en) 2004-08-23
US7700550B2 (en) 2010-04-20
IS6600A (is) 2002-10-29
US20070049519A1 (en) 2007-03-01
US20020022590A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
KR100768488B1 (ko) 글리코펩티드 포스포네이트 유도체
US6858584B2 (en) Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
AU2001261107A1 (en) Glycopeptide phosphonate derivatives
US6620781B2 (en) Glycopeptide carboxy-saccharide derivatives
US6828299B2 (en) Polyhydroxy glycopeptide derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021221

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20030313

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060201

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070329

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070921

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20071012

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20071015

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100930

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110928

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120926

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130930

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130930

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140925

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140925

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150925

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150925

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160927

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160927

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20181001

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20181001

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20200928

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20211101

Termination category: Expiration of duration